We’ve covered health and wellness components and products from Withings since 2014 when we wrote about Glooko glucose tracking software and Withings wearable fitness devices. Withings introduced the ScanWatch hybrid health tech wearable smartwatch at CES 2020. At that time Withings announced the company expected to begin selling the ScanWatch in Europe and the U.S. in the second quarter 2020, pending CE and FDA certifications. CE certification came sooner, but Withings announced this week the ScanWatch received simultaneous FDA clearances to record ECG and SpO2 measurements.
The ScanWatch monitors physical activity, sleep, blood oxygen levels, breathing disturbances, heart rate, and atrial fibrillation. The ScanWatch monitors heart rate with a PPG sensor. If the sensor detects irregular heartbeat it can alert the user to record a medical-grade ECG, according to the company. The user can also use the Withings Health Mate app to send the ECG report to medical professionals. The watch helps detect breathing difficulty or disturbances with an algorithm that analyzes blood oxygen levels, heart rate, movement, and respiratory rate. The algorithm relies on data from the watch’s SpO2 sensor, accelerometer, and optical sensor.
In addition to its health monitoring capabilities, the ScanWatch is an able fitness monitor that tracks steps, calories, elevation, and location. It also tracks running or workout routes with the help of an integrated GPS. According to Withings, the ScanWatch can work with more than 100 third-party apps such as Apple Heath, Google Fit, and MyFitnessPal in addition to the Health Mate app,
The ScanWatch has a stainless steel case and a sapphire glass watch face with a choice of black or white face. The watch is rated water resistant to 5 ATM (165 feet). It runs for up to 30 days per battery charge, Withings says. The ScanWatch will be available for purchase at Withings.com, Amazon, and Best Buy in early November. The price will be $279 with a 38mm case and $299 with a 42mm case.
